AEON Biopharma, Inc.

AEON Biopharma, Inc. (ticker: AEON) is a clinical-stage biopharmaceutical company focused on developing botulinum toxin therapeutics for underserved medical conditions. The company became publicly traded through its business combination with Priveterra Acquisition Corp, a blank-check vehicle that completed its IPO in 2021 and was sponsored by Priveterra Management LLC. Operating within the biotechnology and specialty pharmaceutical sector, AEON filed this Form 10-Q quarterly report with the SEC on May 17, 2023, reflecting its active reporting status as a post-merger public company. For full filings history, deal analytics, and sponsor data on AEON Biopharma and the broader SPAC universe, sign up at SpacDesk.